Androulla N. Miliotou

Androulla N. Miliotou

Auto-generated profile, based on publicly available information

Androulla N. Miliotou


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2018 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
AMAndroulla N. Miliotou
Androulla N. Miliotou
LPLefkothea Papadopoulou
Lefkothea Papadopoulou
Background: Cancer is one of the leading causes of death worldwide. Over the years, a number of conventional cytotoxic approaches for neoplastic diseases has been developed. However, due to their limited effectiveness in accordance with the heterogeneity of cancer cells, there is a constant search for therapeutic approaches with improved outcome, such as immunotherapy that utilizes and enhances the normal capacity of the patient’s immune system. Methods: Chimeric Antigen Receptor (CAR) T-cell therapy involves genetic modification of patient’s autologous T-cells to express a CAR specific for a tumor antigen, following by ex vivo cell expansion and re-infusion back to the patient. CARs are fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signaling domains. This T-cell genetic modification may occur either via viral-based gene transfer methods or nonviral methods, such as DNA-based transposons, CRISPR/Cas9 technology or direct transfer of in vitro transcribed-mRNA by electroporation. Results: Clinical trials have shown very promising results in end-stage patients with a full recovery of up to 92% in Acute Lymphocytic Leukemia. Despite such results in hematological cancers, the effective translation of CAR T-cell therapy to solid tumors and the corresponding clinical experience is limited due to therapeutic barriers, like CAR T-cell expansion, persistence, trafficking, and fate within tumors. Conclusion: In this review, the basic design of CARs, the main genetic modification strategies, the safety matters as well as the initial clinical experience with CAR T-cells are described.

24 April 2019 in Expert Review of Precision Medicine and Drug Development
Verified
Journal Article
Closed access
Ioannis VizirianakisIoannis Vizirianakis
Ioannis Vizirianakis
AMAndroulla N. Miliotou
Androulla N. Miliotou
Georgios MystridisGeorgios Mystridis
Georgios Mystridis
Eleftherios AndriotisEleftherios Andriotis
Eleftherios Andriotis
Ioannis I. AndreadisIoannis I. Andreadis
Ioannis I. Andreadis
DFDimitrios G. Fatouros
Dimitrios G. Fatouros
Introduction: Nowadays, nanotechnology and genomics contribute knowledge and innovative practices, enabling pharmacological interventions as well as theraputic decisions to be applicable on a personal basis, i.e., establishing precision (personalized) medicine approaches into the clinical setting. However, the dynamics and the evolution capacity of organisms over time necessitate the advancement of powerful interdisciplinary tools, population-based pharmacological methodologies, as well as the application of translational methodologies with clinical implementation capabilities. Areas covered: Even for newly emerged techniques, like three-dimensional (3D) bioprinting nanoplatforms and in vitro transcribed (IVT)-mRNA therapeutics, the patients’ heterogeneity still hinders their potential exploitation in a broader perspective and clinical outcome burden. It is thus essential that the recently developed computational physiologically-based pharmacokinetic (PBPK) models present tools aiming to predict differential pharmacological response in patient groups and to allow cost-effective individualized dosage adjustments for populations worldwide. Expert opinion: The recent advancements in IVT-mRNA therapeutics and 3D bioprinting technologies, along with the capabilities of PBPK modeling to delineate the issue of interpatient heterogeneity, will be presented and discussed. Also, the integration of core interdisciplinary infrastructures will be included in a manner to better serve the task of more efficiently and productively achieving precision medicine interventions in the everyday clinical practice.

20 January 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
Panoraia I. SiafakaPanoraia I. Siafaka
Panoraia I. Siafaka
ECE ÖZCAN BÜLBÜLECE ÖZCAN BÜLBÜL
ECE ÖZCAN BÜLBÜL
AMAndroulla N. Miliotou
Androulla N. Miliotou
IKIoannis D. Karantas
Ioannis D. Karantas
MOMehmet Evren Okur
Mehmet Evren Okur
Neslihan Üstündağ OkurNeslihan Üstündağ Okur
Neslihan Üstündağ Okur

12 May 2025 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Panoraia I. SiafakaPanoraia I. Siafaka
Panoraia I. Siafaka
AMAndroulla N. Miliotou
Androulla N. Miliotou
MOMehmet Evren Okur
Mehmet Evren Okur
GGGökçe Karaotmarlı Güven
Gökçe Karaotmarlı Güven
IKIoannis Karantas
Ioannis Karantas
Neslihan Üstündağ OkurNeslihan Üstündağ Okur
Neslihan Üstündağ Okur
Wounds are broadly classified into acute and chronic types, with chronic wounds being those that cannot heal within 4 to 12 weeks despite treatment. There is a growing interest in efficient and cost-effective wound healing though the drug delivery of active molecules. Natural compounds such as phytochemicals, as well as synthetic molecules with antimicrobial or anti-inflammatory growth factors, can impact tissue regeneration and prevent wound infections. Nanotechnology-based systems, such as polymeric and inorganic nanoparticles and electrospun nanofibrous matrices loaded with phytochemicals, can enhance the therapeutic efficacy of active molecules through improved bioavailability and targeted delivery. This review summarizes the most current advanced applications combining phytochemicals and nanoformulations with promising wound healing potential. Various nanosystems loaded with phytochemicals have been identified, such as silver nanocarriers, zein-based nanoparticles, and various known polymers, which can be utilized to develop electrospun fibrous structures loaded with phytoremedies. Despite the incorporation of these remedies into traditional medicine for a long time, further clinical studies are essential to determine their pharmacological properties, safety concerns, and therapeutic efficacy.

1 November 2024 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
IKIoannis Karantas
Ioannis Karantas
AMAndroulla N. Miliotou
Androulla N. Miliotou
Panoraia I. SiafakaPanoraia I. Siafaka
Panoraia I. Siafaka
Background: Hyperuricemia belongs to metabolic syndromes where increased uric acid levels are identified in the blood serum. Such a syndrome could be responsible for kidney stone formation, gout, hypertension, and chronic kidney diseases. It has been reported that cardiovascular risks have been linked with hyperuricemia. Gout is of the most frequent manifestations due to hyperuricemia; its management involves various pharmacological available options and dietary changes. Throughout the literature, various dosage forms are studied as alternative options to the present drug delivery systems. Objective: To update and summarize the current information for gout and hyperuricemia management. Methods: Authors have performed a thorough literature research from 2010-2023 using keywords such as hyperuricemia, gout, diagnosis, guidelines, drug delivery and clinical trials. The databases used were PubMed, ScienceDirect. According to our inclusion criteria, all studies which include the previous terms, as well as drugs or other molecules that can be applied for gout and/or hyperuricemia management, were added. Results: In this article, authors have summarized the pathogenesis, diagnosis and updated guidelines for gout and hyperuricemia management. Moreover, the authors have reviewed and discussed current drug delivery systems found in the literature, including drugs targeting the above disorders. Finally, the available clinical trials assessing the efficacy of newer drugs or combinations of the past ones, are being discussed. Conclusion: The available drugs and dosage forms are limited, and therefore, scientific society should focus on the development of more efficient drug delivery systems for hyperuricemia and gout management.

15 January 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
AMAndroulla N. Miliotou
Androulla N. Miliotou
AKAndria Kotsoni
Andria Kotsoni
LZLefteris Zacharia
Lefteris Zacharia
Neurodegenerative diseases are currently among the most devastating diseases with no effective disease-modifying drugs in the market, with Alzheimer’s disease (AD) being the most prevalent. AD is a complex multifactorial neurodegenerative disorder characterized by progressive and severe cognitive impairment and memory loss. It is the most common cause of progressive memory loss (dementia) in the elderly, and to date, there is no effective treatment to cure or slow disease progression substantially. The role of adrenergic receptors in the pathogenesis of Alzheimer’s disease and other tauopathies is poorly understood or investigated. Recently, some studies indicated a potential benefit of drugs acting on the adrenergic receptors for AD and dementias, although due to the heterogeneity of the drug classes used, the results on the whole remain inconclusive. The scope of this review article is to comprehensively review the literature on the possible role of adrenergic receptors in neurodegenerative diseases, stemming from the use of agonists and antagonists including antihypertensive and asthma drugs acting on the adrenergic receptors, but also from animal models and in vitro models where these receptors have been studied. Ultimately, we hope to obtain a better understanding of the role of these receptors, identify the gaps in knowledge, and explore the possibility of repurposing such drugs for AD, given their long history of use and safety.